(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new report, “Drug Manufacturer Strategies for Keeping Drug Costs High,” on pharmaceutical industry pricing tactics that increase prescription drug costs for patients. The report, conducted by the research firm Visante,
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Energy and Commerce Committee’s inclusion of full repeal of the rebate rule in the committee’s legislative recommendations for its budget reconciliation bill
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Biden administration’s plan for high drug prices: “While we review the recently released Comprehensive Plan for Addressing High Drug Prices report,
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WHAT IS WHITE BAGGING… There’s a lot of jargon in
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
The Pharmaceutical Care Management Association recently submitted a letter to the Council of Economic Advisers. Click here for the letter PCMA’s letter includes the following points: 1. The report offers no evidence to back its claim that the drug marketplace
PBMs leverage competition between drugs to create savings for patients.
Dr. Lawton Burns Says PBMs are Unfairly Blamed for High Drug Prices, Should Look At Big Drug Companies In case you missed it, Lawton R. Burns, PhD, professor of health care management at the Wharton School of the University of
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
©2024 PCMA. All Rights Reserved.
